Abstract:Abstract The mitogen-activated protein kinases (MAPK) pathway, often known as the RAS-RAF-MEK-ERK signal cascade, is the most frequently mutated signal pathway in cancer, which makes the components of this pathway attractive targets for anticancer drug development. The MAPK pathway is aberrantly activated in more than 30% of human cancers through a high frequency of genetic alteration. BRAF mutation has been identified in colorectal (10%), thyroid (∼50%) and melanoma (60%) tumors, whereas RAS is mutated in melanoma (20%), colorectal (50%) and pancreatic (90%) tumors. Thus far, inhibitors targeting the upstream BRAF and MEK have been the focus of past decades and achieved great clinical successes, but remained being challenged by the acquired resistance due to genetic alterations in RAS, BRAF or MEK. Therefore, targeting the downstream ERK is believed to exhibit potential advantages in both effectively shutting down MAPK signaling cascade and overcoming the resistance to upstream targets. Toward that end, we developed a novel ERK1/2 inhibitor, HH2710, which is a highly potent and selective inhibitor of ERK1 and ERK2 with IC50 of 4.5, 4.9 nM, respectively. HH2710 significantly inhibited the downstream RSK phosphorylation in a dose-dependent manner in both BRAF and RAS mutant cancer cell lines. HH2710 strongly inhibited the proliferation of most BRAF mutated cancer cell and a proportion of RAS mutated cells, with IC50s ranging from 0.2 to 4.5 μM. In tumor xenograft models, HH2710 showed significant antitumor activity at the doses of 15, 30, and 60 mg/kg (twice per day, given orally) with the relative tumor volume at the endpoint (T/C value) of 51.0%, 18.1%, and 11.7% respectively, exhibiting improved efficacy over the front runner molecule in clinical development. Summary of pharmacokinetic parameters are listed in Table 1. The full in vitro and in vivo preclinical characterizations of HH2710 will be presented. Table 1, Pharmacokinetic parameters of HH2710 in mouse, SD rats and Beagle dogs ParametersnCmax*nAUC0-t*t1/2TmaxFµg/mLµg•h/mLhh(%)Mouse, PO0.5031.811.12.065Rat, PO0.2691.773.02.068Dog, PO0.3381.642.01.573*nCmax: Cmax/dose; nAUC0-t : AUC0-t/dose Citation Format: Lei Li, Min Huang, Leping Li, Yi Chen, Shuai Tang, Yi Su, Ruiping Dong, Jian Ding, Meiyu Geng. HH2710, a highly potent and selective erk1/2 inhibitor for the treatment of mapk mutant tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3760.

Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader.

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders

Remodeling Tumor-Associated Macrophage for Anti-Cancer Effects by Rational Design of Irreversible Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2

Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer

Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells.

Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders

Abstract 3760: HH2710, a Highly Potent and Selective Erk1/2 Inhibitor for the Treatment of Mapk Mutant Tumors

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-Met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(quinolin-6-ylmethyl)-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1h-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment Of

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders

Non-'classical' MEKs: A review of MEK3-7 inhibitors

2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)

Optically Activated MEK1/2 Inhibitors (Opti-Meki) As Potential Antimelanoma Agents

Design, Synthesis, and Biological Evaluation of Proteolysis-Targeting Chimeras as Highly Selective and Efficient Degraders of Extracellular Signal-Regulated Kinase 5

Abstract 5902: Targeting MAPK-driven tumors via inhibition of MAP2K4

Design, Synthesis, and Antitumor Activity Evaluation of Proteolysis-Targeting Chimeras as Degraders of Extracellular Signal-Regulated Kinases 1/2

Dual Inhibition of Allosteric Mitogen-Activated Protein Kinase (MEK) and Phosphatidylinositol 3-Kinase (PI3K) Oncogenic Targets with a Bifunctional Inhibitor

Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy

Structure-based design and synthesis of 5-benzyl-2-phenylpyrimidin-4(3H)-one derivatives as novel MEK1 inhibitors